Hercules, CA — October 6, 2014 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of new PrimePCR™ Rat Genome Assays for quantitative real-time PCR (qPCR). This expands Bio-Rad’s line of wet-lab validated assays that includes human and mouse genome assays.
Assay validation is one of the most important steps in qPCR but is sometimes ignored because researchers may be unaware of its critical importance in generating accurate results. Validating assays can be laborious and time-consuming, especially when they do not work and need to be redesigned and reordered. While some companies claim to sell prevalidated assays, this assertion often refers to software predictions as opposed to wet-lab validation.
Bio-Rad’s PrimePCR Assays, however, are fully wet-lab validated for specificity, efficiency, and sensitivity, and help researchers adhere to industry best practices known as MIQE (minimum information for publication of quantitative real-time PCR experiments). As part of this validation process, Bio-Rad scientists validate all PCR products using next-generation sequencing, verifying the percentage of on-target amplification. In addition, all of the validation raw data are available to the customer.
Meredith Tennis, PhD, a researcher at the University of Colorado Cancer Center, has been using PrimePCR Assays for cancer chemotherapy prevention studies.
“We choose PrimePCR Assays because they are expertly validated, helping us meet MIQE guidelines,” said Tennis. “Through PrimePCR, we can confidently assess every gene we are interested in on the first try, saving us both time and money.”
Researchers will be able to order PrimePCR Rat Genome Assays as individual assays (desalted or HPLC-purified), or build a custom plate (96- or 384-well). Assays are available for more than 20,000 rat genes as SYBR®- and probe-based assays with a choice of five different fluorophores.
In addition, SYBR® and probe PrimePCR PreAmp Assays will be available for the rat genome. These preamplification assays allow researchers who are working with limited samples to look at more targets during their qPCR experiments. Bio-Rad’s PreAmp Supermix, along with PrimePCR PreAmp Assays, produces consistent gene expression results while delivering the industry’s lowest bias.
For more information on Bio-Rad’s PrimePCR products, please visit www.bio-rad.com/PrimePCRpr.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs approximately 7,750 people worldwide and had revenues exceeding $2.1 billion in 2013. For more information, visit our website at www.bio-rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company’s risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.
For more information contact:
Richard Kurtz
Bio-Rad
510-741-5638
Richard_Kurtz@bio-rad.com
Ken Li
Chempetitive Group
312-997-2436 x 112
kli@chempetitive.com
Help employers find you! Check out all the jobs and post your resume.
